ENDRA Life Sciences (NASDAQ:NDRA) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of ENDRA Life Sciences (NASDAQ:NDRAGet Rating) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Separately, HC Wainwright lowered their price target on shares of ENDRA Life Sciences from $6.00 to $5.00 and set a buy rating for the company in a research report on Thursday, April 7th.

Shares of NDRA opened at $0.22 on Thursday. The firm’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.60. ENDRA Life Sciences has a 1-year low of $0.18 and a 1-year high of $2.44.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share for the quarter. During the same quarter in the previous year, the company earned ($0.10) EPS. Research analysts expect that ENDRA Life Sciences will post -0.19 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Morgan Stanley raised its holdings in ENDRA Life Sciences by 2,455.4% in the first quarter. Morgan Stanley now owns 220,634 shares of the company’s stock worth $573,000 after buying an additional 212,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in ENDRA Life Sciences by 2.3% in the third quarter. Geode Capital Management LLC now owns 323,679 shares of the company’s stock worth $559,000 after buying an additional 7,197 shares during the last quarter. Renaissance Technologies LLC purchased a new position in ENDRA Life Sciences in the fourth quarter worth about $150,000. Royal Bank of Canada grew its stake in shares of ENDRA Life Sciences by 65.3% in the second quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock worth $55,000 after acquiring an additional 10,000 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of ENDRA Life Sciences in the fourth quarter worth approximately $50,000. 10.03% of the stock is owned by institutional investors and hedge funds.

ENDRA Life Sciences Company Profile (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

See Also

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.